Merus N.V. (Nasdaq: MRUS) to Ring The Nasdaq Stock Market Closing Bell in celebration of IPO
May 19 2016 - 6:00AM
What:Merus N.V. (Nasdaq:MRUS), a
clinical-stage immuno-oncology company developing innovative
bispecific antibody therapeutics, will visit the Nasdaq MarketSite
in Times Square to celebrate its initial public offering (IPO).
In honor of the occasion, Ton Logtenberg,
Ph.D, Chief Executive Officer, will ring the Closing
Bell.
Where:Nasdaq MarketSite – 4 Times
Square – 43rd & Broadway – Broadcast Studio
When:Thursday, May 19, 2016 – 3:45
p.m. to 4:00 p.m. ET
Merus N.V. Media Contact:Eliza
Schleifstein, Argot Partners(917)
763-8106Eliza@argotpartners.com
Nasdaq MarketSite:Emily Pan(646)
441-5120emily.pan@nasdaq.com
Feed Information:Fiber Line
(Encompass Waterfront): 4463
Gal 3C/06C 95.05 degrees West 18 mhz Lower DL 3811
Vertical FEC 3/4 SR 13.235 DR 18.295411 MOD 4:2:0 DVBS QPSK
Social Media:For multimedia
features such as exclusive content, photo postings, status updates
and video of bell ceremonies, please visit our Facebook
page:http://www.facebook.com/NASDAQ.
For photos from ceremonies and events, please visit
our Instagram page:http://instagram.com/nasdaq
For livestream of ceremonies and events, please
visit our YouTube page:http://www.youtube.com/nasdaq/live
For news tweets, please visit our Twitter
page:http://twitter.com/nasdaq
For exciting viral content and ceremony photos,
please visit our Tumblr page:http://nasdaq.tumblr.com/
Webcast: A live stream of the
Nasdaq Closing Bell will be available at:
https://new.livestream.com/nasdaq/live or
http://www.nasdaq.com/about/marketsitetowervideo.asx
Photos: To obtain a hi-resolution
photograph of the Market Close, please go to
http://business.nasdaq.com/discover/market-bell-ceremonies and
click on the market close of your choice.
About Merus N.V.Merus is a
clinical-stage immuno-oncology company developing innovative
bispecific antibody therapeutics, referred to as Biclonics.
Biclonics are based on the full-length IgG format, are manufactured
using industry standard processes and have been observed in
preclinical studies to have several of the same features of
conventional monoclonal antibodies, such as long half-life and low
immunogenicity. Merus’ lead bispecific antibody candidate,
MCLA-128, is being evaluated in a Phase 1/2 clinical trial in
Europe as a potential treatment for HER2-expressing solid tumors.
Merus’ second bispecific antibody candidate, MCLA-117, is being
developed as a potential treatment for acute myeloid leukemia. The
Company also has a pipeline of proprietary bispecific antibody
candidates in preclinical development, including MCLA-158, which is
designed to bind to cancer stem cells and is being developed as a
potential treatment for colorectal cancer and other solid tumors,
and Biclonics designed to bind to various combinations of
immunomodulatory molecules, including PD-1 and PD-L1.
About NasdaqNasdaq (Nasdaq:NDAQ)
is a leading provider of trading, clearing, exchange technology,
listing, information and public company services across six
continents. Through its diverse portfolio of solutions, Nasdaq
enables customers to plan, optimize and execute their business
vision with confidence, using proven technologies that provide
transparency and insight for navigating today's global capital
markets. As the creator of the world's first electronic stock
market, its technology powers more than 70 marketplaces in 50
countries, and 1 in 10 of the world's securities transactions.
Nasdaq is home to more than 3,700 listed companies with a market
value of approximately $9.3 trillion and nearly 17,000 corporate
clients. To learn more, visit: nasdaq.com/ambition or
business.nasdaq.com.
-NDAQA-
Nasdaq (NASDAQ:NDAQ)
Historical Stock Chart
From Mar 2024 to Apr 2024
Nasdaq (NASDAQ:NDAQ)
Historical Stock Chart
From Apr 2023 to Apr 2024